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ABSTRACT
We recently discovered that truncated glioma-associated oncogene homolog 1 
(TGLI1) is highly expressed in glioblastoma (GBM) and linked to increased GBM 
vascularity. The mechanisms underlying TGLI1-mediated angiogenesis are unclear. 
In this study, we compared TGLI1- with GLI1-expressing GBM xenografts for 
the expression profile of 84 angiogenesis-associated genes. The results showed 
that expression of six genes were upregulated and five were down-regulated in 
TGLI1-carrying tumors compared to those with GLI1. Vascular endothelial growth 
factor-C (VEGF-C) and tumor endothelial marker 7 (TEM7) were selected for further 
investigations because of their significant correlations with high vascularity in 
135 patient GBMs. TGLI1 bound to both VEGF-C and TEM7 gene promoters. Conditioned 
medium from TGLI1-expressing GBM cells strongly induced tubule formation of 
brain microvascular endothelial cells, and the induction was prevented by VEGF-C/
TEM7 knockdown. Immunohistochemical analysis of 122 gliomas showed that TGLI1 
expression was positively correlated with VEGF-C, TEM7 and microvessel density. 
Analysis of NCBI Gene Expression Omnibus datasets with 161 malignant gliomas 
showed an inverse relationship between tumoral VEGF-C, TEM7 or microvessel density 
and patient survival. Together, our findings support an important role that TGLI1 plays 
in GBM angiogenesis and identify VEGF-C and TEM7 as novel TGLI1 target genes of 
importance to GBM vascularity.
INTRODUCTION
Glioblastoma (GBM) is the most frequent and 
most lethal brain tumor in adults [1]. Prognosis of 
GBM is poor with median survival of 14 months and 
less than five percent of patients surviving five years 
after diagnosis [1, 2]. GBM (grade IV glioma) is more 
angiogenic, proliferative, and invasive than gliomas at 
lower grades [3]. Angiogenesis plays a significant role 
in GBM pathobiology largely because GBM poses a 
considerable metabolic demand for oxygen delivery and 
waste removal to sustain its high rates of cell proliferation 
and metabolism. In line with these notions, GBM 
vascularity is associated with poor patient prognosis [4, 5]. 
Consequently, anti-angiogenic therapy for GBM has been 
developed, most prominently in the form of bevacizumab, 
a monoclonal antibody targeting vascular endothelial 
growth factor A (VEGF-A). While bevacizumab treatment 
initially results in a biological response of tightening 
the blood-brain barrier, the treatment does not prevent 
aggressive local and diffusive spread [6–8]. Resistance 
to anti-VEGF-A therapy suggests there may be other 
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angiogenic factors or pathways that play a role in GBM 
angiogenesis. For example, VEGF-D was shown to be 
over-expressed in GBM comparably to VEGF-A [9].
Glioma-associated oncogene homolog 1 (GLI1) is 
a zinc finger transcription factor serving as the terminal 
effector of the sonic hedgehog (Shh) signaling pathway 
[10]. Our lab discovered a novel variant of GLI1, called 
truncated GLI1 (TGLI1), in which the entire exon III and 
a portion of exon IV are excluded by alternative splicing 
[11]. The splicing of this region results in an in-frame 
deletion of 123 bp (41 amino acids) while retaining all of 
the functional domains of GLI1 and regulating known GLI1 
genes to a similar extent as GLI1 [11]. However, evidence 
to date indicates that TGLI1 has gained the ability to 
transcriptionally activate several genes that are not regulated 
by GLI1 and consequently, gained the propensity to promote 
tumor migration and invasion. [11–13] Interestingly, TGLI1 
was only detectable in cell lines, patient-derived xenografts, 
and primary specimens of GBM, but undetectable in normal 
brain or other normal human tissues we had examined [11]. 
Our most recent study [14] further linked TGLI1 to GBM 
vascularity as we observed that GBM xenografts with 
increased TGLI1 being more vascularized; however, the 
mechanisms underlying this link are still elusive.
Our previous data indicate TGLI1 has increased 
expression in GBM relative to normal brain tissue and 
promotes tumor growth with greater vascularity [14]. 
However, the underlying mechanisms for TGLI1-induced 
GBM angiogenesis are not fully understood. To help fill 
this knowledge gap, we subjected TGLI1- and GLI1-
expressing tumors to an angiogenesis PCR array and 
found that TGLI1-expressing tumors showed increased 
expression of six genes and decreased expression of five 
genes. Among these identified genes, we subsequently 
focused on vascular endothelial growth factor-C (VEGF-C) 
and tumor endothelial marker 7 (TEM7) because of their 
positive correlations with high vascularity as determined 
by analyzing NCBI Gene Expression Omnibus (GEO) 
datasets derived from 135 patient GBMs. We further 
observed that TGLI1 transcriptionally upregulates 
VEGF-C and TEM7 gene expression and that TGLI1 
levels were significantly associated with microvessel 
density, VEGF-C levels, and TEM7 levels in a cohort of 
glioma patients. Both TGLI1 target genes are associated 
with worse survival of patients with malignant gliomas. 
In summary, our study provides new insights into the 
molecular underpinning of GBM abnormal angiogenesis.
RESULTS
VEGF-C and TEM7 are upregulated in 
highly vascularized TGLI1-expressing 
xenograft tumors
In our initial discovery of TGLI1, we observed 
that TGLI1-expressing GBM xenografts showed greater 
expression of CD24 with evidence of greater invasiveness 
compared to GLI1-expressing GBM xenografts [11]. 
More recently, we showed that TGLI1-expressing GBM 
xenografts were more proliferative and more vascularized 
compared to GLI1-expressing tumors [14]. Since 
angiogenesis is regulated by the balance of pro- and anti-
angiogenic factors in a given microenvironment [15], 
we examined whether TGLI1 regulated expression of 
angiogenesis-associated genes. To this end, we analyzed 
xenograft tumors derived from stable TGLI1- or GLI1-
expressing GBM cells in our recent studies [11, 14] using 
an angiogenesis PCR array, which detects expression of 84 
human genes related to angiogenesis (Fig. 1a). The results 
indicated that six genes were expressed at significantly 
higher levels, while five genes expressed at lower levels, 
in TGLI1-expressing tumors than GLI1-expressing 
tumors (Fig. 1c and Tables S1 and S2 in Supplementary 
Information). To provide an additional filter to select genes 
for further investigations, we analyzed NCBI GEO public 
datasets (GSE4271 [16] and GSE4412 [17]; 135 primary 
GBMs) to determine the degrees to which these genes 
are correlated with CD31, a vascular endothelial marker, 
in patient GBMs. As indicated in Fig. 1b, expression of 
HPA1, TEM7 and VEGF-C, but not FGF1, VEGF-A or 
AKT1, were positively correlated with levels of CD31 
( p < 0.05). Linear regression plots in Fig. 1c indicate that 
TEM7, VEGF-C and HPA1 expression significantly and 
positively correlate with CD31 in GBM samples.
Next, we confirmed the positive associations 
of TGLI1 with TEM7 and VEGF-C at the mRNA 
and protein levels using GBM xenografts (Fig. 1e). 
These associations were further validated using 
immunohistochemistry (IHC) as the TGLI1 xenografts 
showed higher expression of VEGF-C, TEM7, and 
HPA1 (Fig. 1e). Representative images of IHC-analyzed 
xenografts are shown in Fig. 1f. Taken together, the 
results in Fig. 1 indicate that TGLI1 may promote GBM 
neo-vascularity by upregulating the expression of several 
angiogenic factors.
TGLI1 upregulates expression of VEGF-C 
and TEM7
We next aimed to determine whether TGLI1 can 
directly upregulate VEGF-C and TEM7. Of note, the 
direct link between TGLI1 and HPA1was reported in our 
recent study [14]; therefore, we subsequently focused our 
efforts on VEGF-C and TEM7 in this study. VEGF-C is a 
member of the VEGF family that is regarded as a trophic 
factor for neural progenitors in the vertebrate embryonic 
brain [18]. VEGF-C can bind to and activate VEGFR3, 
leading to lymphangiogenesis [19, 20]. VEGF-C can also 
bind to and activate VEGFR2, leading to angiogenesis 
and cell growth. [19–21] TEM7 is a type I transmembrane 
protein with a large extracellular domain [22] whose 
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biological function is still unclear. TEM7 has been shown 
to interact with extracellular matrix components and 
may play a role in cell migration, invasion, and capillary 
morphogenesis [23–26]. We transiently transfected 
U87MG cells with either TGLI1 or GLI1, or the control 
empty vector. Total RNA was subjected to RT-PCR 
and we observed greater mRNA levels of VEGF-C and 
TEM7 in TGLI1-expressing cells compared to GLI1- or 
vector-expressing cells (Fig. 2a). Fig. 2b shows that the 
protein levels of VEGF-C and TEM7 were also greater 
in TGLI1-expressing cells compared to GLI1- or vector-
expressing cells. The conditioned medium of these 
cells was collected and subjected to VEGF-C ELISA to 
determine if TGLI1 made cells secrete more VEGF-C 
than GLI1. The results showed that TGLI1-expressing 
cells had significantly higher secretion of VEGF-C than 
GLI1- or vector-expressing cells (Fig. 2c). We then 
conducted the chromatin immunoprecipitation (ChIP) 
assay and found that TGLI1 bound to both VEGF-C 
and TEM7 gene promoters more strongly than GLI1 
(Fig. 2d). The enrichment of TGLI1 occurred within the 
first 600 bp of the gene promoters, which was identified 
using different primer sets that scanned the proximal 3 kb 
of these promoters. Together, these results indicate the 
novel finding that TGLI1 can upregulate VEGF-C and 
TEM7 expression via direct binding to the respective gene 
promoters.
VEGF-C contributes to TGLI-induced 
angiogenesis
Next, we studied whether VEGF-C is a significant 
contributor to TGLI1-induced angiogenesis. As shown 
in Fig. 3a, knockdown using siRNA directed to 
VEGF-C effectively reduced VEGF-C levels in TGLI1-
expressing GBM cells. Non-specific (NS) siRNA served 
as a negative control. Fig. 3b shows that VEGF-C 
knockdown significantly reduced TGLI1-induced 
Figure 1: VEGF-C and TEM7 are upregulated in highly vascularized TGLI1-expressing GBM xenografts. a. TGLI1- 
and GLI1-expressing GBM xenografts were generated by subcutaneous flank inoculation in nude mice in our previous study [11]. The 
resulting TGLI1-expressing tumors showed greater size and vascularity than GLI1-expressing tumors. Total RNA was isolated from three 
TGLI1- and three GLI1-expressing tumors and subjected to RT-PCR and the angiogenesis PCR array. b. Six pro-angiogenesis genes were 
upregulated in TGLI1 tumors compared to GLI1 tumors, as indicated by the angiogenesis PCR array. Analysis of two GEO public datasets 
(GSE4412 and GSE4271; 135 primary GBMs) showed that HPA1, TEM7 and VEGF-C were positively correlated with the vascular 
endothelial marker CD31 ( p < 0.05). c. Linear regression plots, derived from the GEO analysis, indicate that VEGF-C, TEM7 and HPA1 
significantly correlate with CD31 in patient GBMs (N = 135). d. RT-PCR and western blotting showed that TGLI1 xenografts expressed 
higher levels of VEGF-C, TEM7, and HPA1 than those with GLI1. e. IHC confirmed that TGLI1 xenografts expressed higher expression 
of VEGF-C, TEM7, and HPA1 than GLI1 tumors. Histologic scores (H-scores) were computed from percent positivity (A%, A = 1–100) 
and intensity (B = 0–3) using the equation, H-Score = A x B. Student’s t-test was used to compute p-values. f. Representative images of 
IHC-analyzed xenografts.
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secretion of VEGF-C. Next, we determined the effect 
of VEGF-C knockdown in GBM cells on in vitro 
angiogenesis of microvascular endothelial cells. To this 
end, TGLI1- or GLI1-expressing U87MG cells were 
transfected with either control or VEGF-C siRNA. 
Conditioned medium from these cells was placed on 
human brain microvascular endothelial cells, which were 
monitored for tubule formation (Fig. 3c). Knockdown 
of VEGF-C in TGLI1-expressing cells significantly 
reduced both total tubule length and branch points of 
human brain microvascular endothelial cells compared 
to control siRNA (Figs. 3c-3e). These data suggest that 
VEGF-C may play an important role in TGLI1-induced 
angiogenesis.
TEM7 contributes to TGLI1-induced 
angiogenesis
We next determined whether TEM7 is a significant 
contributor to TGLI1-induced angiogenesis. Knockdown 
of TEM7 using siRNA significantly reduced TEM7 
expression in TGLI1-expressing GBM cells (Fig. 4a). To 
determine the contribution of TEM7 to TGLI1-induced 
in vitro angiogenesis, we collected conditioned medium 
from TGLI1-expressing GBM cells with or without TEM7 
knockdown and incubated the conditioned media on 
human brain microvascular endothelial cells and monitored 
the extent of tubule formation (Fig. 4b). Conditioned 
medium from TGLI1-expressing cells with knockdown of 
TEM7 induced significantly lower total tubule lengths and 
branch points compared to TGLI1-expressing cells with 
non-specific control siRNA (Figs. 4c-4e). These results 
suggest TEM7 is also a potentially important mediator of 
TGLI1-induced angiogenesis.
TGLI1 levels correlate with microvessel density 
in patients with gliomas
We previously published the development of rabbit 
polyclonal TGLI1-specific antibodies that do not cross-
react with GLI1 and we have used the antibodies to 
selectively detect TGLI1 via immunohistochemistry (IHC) 
[14]. Using the TGLI1-specific and CD31 antibodies in 
IHC, we assessed whether TGLI1 expression is related 
to microvessel density in a cohort of glioma patients 
consisting of 134 tissues (122 glioma across all grades 
and 12 normal brain). CD31 signals mark vascular 
endothelial cells and were used to derive microvessel 
density. As shown in Fig. 5a, we observed a statistically 
significant correlation between TGLI1 expression and 
microvessel density in this cohort. We next limited our 
analysis to gliomas only (grades I-IV) and the statistically 
significant correlation between TGLI1 levels and 
microvessel density remained (Fig. 5b). We also observed 
that TGLI1 levels were significantly higher in GBM 
tumors compared to normal brain (Fig. 5c). Additionally, 
Figure 2: TGLI1 upregulates VEGF-C and TEM7 gene expression. a and b. Transient expression of TGLI1 enhances 
expression of VEGF-C and TEM7 in GBM cells. TGLI1, GLI1, or an empty vector were transfected into U87MG GBM cells and the total 
RNA or total protein was isolated from these cells and subjected to RT-PCR (a) or western blotting (b), respectively. c. ELISA shows that 
the TGLI1-overexpressing GBM cells secreted more VEGF-C into the conditioned medium compared to the cells with GLI1 or control 
vector. d. The ChIP assay shows that TGLI1 bound to the VEGF-C and TEM7 gene promoters more strongly than GLI1. IgG was used as 
negative control for an antibody recognizing both TGLI1 and GLI1. Chromatin input was used in PCR as loading controls.
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microvessel density was significantly higher in GBM 
samples compared to normal brain (Fig. 5d), consistent 
with the pro-angiogenic nature of GBM. Fig. 5e shows 
a representative case of GBM with high nuclear TGLI1 
expression and high vascularity (visualized with CD31 
IHC) as well as a normal brain tissue with low levels of 
TGLI1 and vascularity. Furthermore, GEO analysis of 161 
malignant gliomas indicated that high CD31 expression 
(indicative of high vascularity) predicted poor patient 
survival ( p = 0.0008; Fig. 5f). Cumulatively, these data 
further support an important role that TGLI1 plays in 
GBM angiogenesis.
TGLI1 levels correlate with VEGF-C in patients 
with GBM
Considering that we found VEGF-C as a novel 
direct target of TGLI1, we next wanted to assess the 
relationship of VEGF-C and TGLI1 in patients. Therefore, 
we assessed the expression of both VEGF-C and TGLI1 in 
Figure 3: TGLI1 promotes in vitro angiogenesis via VEGF-C. a, b. VEGF-C knockdown was effective. U87MG cells expressing 
TGLI1 or GLI1 were transfected with siRNA directed to VEGF-C or non-specific (NS) control siRNA. Total RNA was isolated and 
subjected to RT-PCR (a). Conditioned medium was subjected to VEGF-C ELISA assay (b). Student t-test was used to calculate p-values. 
c–e. Tubule formation assay showed that VEGF-C expression knockdown of VEGF-C reduced the ability of TGLI1-expressing GBM cells 
to promote angiogenesis of human brain microvascular endothelial cells. Representative images are shown in (c). Total tubule length was 
determined and shown in (d). Number of branch points was counted and shown in (e). Student t-test was used to calculate p-values.
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Figure 4: TGLI1 promotes in vitro angiogenesis via TEM7. a. TEM7 knockdown was efficient. U87MG cells expressing TGLI1 
or GLI1 were transfected with TEM7 or control NS siRNA. Total RNA was isolated and subjected to RT-PCR. b–d. Tubule formation assay 
showed that TEM7 expression knockdown reduced the propensity of TGLI1-expressing GBM cells to promote angiogenesis of human 
brain microvascular endothelial cells. Representative images are shown in (b). Total tubule length was calculated and shown in (c). Number 
of branch points was counted and shown in (d). Student t-test was used to calculate p-values.
Figure 5: TGLI1 levels are positively associated with microvessel density in patient gliomas. a. TGLI1 expression positively 
correlates with microvessel density. A tumor microarray with 134 tissues (122 gliomas across all grades and 12 normal brain tissues) was 
subjected to IHC with antibodies for TGLI1 (for H-score) and CD31 (for microvessel density). Pearson Correlation was used. b. TGLI1 
positively correlated with microvessel density in 122 glioma tissues across all grades. Pearson Correlation was used. c. TGLI1 was expressed at 
higher levels in GBM tumors compared to normal brain tissues. Student t-test was used. d. Microvessel density was higher in GBM tumors than 
in normal brain tissues. Student t-test was used. e. Representative images of IHC-analyzed tissues. f. GEO data mining analysis of 161 malignant 
gliomas indicated that high CD31 expression predicted poor patient survival. Red: tumors with high CD31. Green: tumors with low CD31.
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122 patient gliomas across all grades (I-IV) plus 12 normal 
brain tissues. The tissues were analyzed by IHC with 
antibodies for VEGF-C or TGLI1 followed by histological 
scoring. We observed a strongly significant correlation 
between TGLI1 levels and VEGF-C levels in these tissues 
(Fig. 6a). We next limited our analysis to gliomas only 
(I-IV) and the statistically significant correlation between 
TGLI1 and VEGF-C persisted (Fig. 6b) indicating that 
VEGF-C expression is associated with TGLI1 levels 
in tumors. Consistent with TGLI1, we also found that 
VEGF-C levels were significantly higher in GBM tumors 
compared to normal brain tissue (Fig. 6c). Fig. 6d shows 
TGLI1 and VEGF-C expression for a patient with high 
TGLI1 and high VEGF-C expression whereas we did 
not detect any positive signal in normal brain tissue. 
Furthermore, GEO analysis of 161 malignant gliomas 
indicated, for the first time, that high VEGF-C expression 
predicted shortened patient survival ( p = 0.0294; Fig. 6e).
These data indicate TGLI1 levels correlate with VEGF-C 
in patient GBMs and suggest that TGLI1 may contribute 
to poor clinical outcome of GBM patients through 
upregulating VEGF-C expression.
TGLI1 levels correlate with TEM7 in 
patient GBMs
To further investigate the relationship between 
TGLI1 and TEM7, we determined their expression 
levels in 122 patient gliomas with varying grades 
(I-IV) plus 12 normal brain tissues using IHC. The 
tissues underwent IHC with antibodies for TEM7 or 
TGLI1 following by histological scoring. Levels of 
TEM7 were significantly correlated with levels of TGLI1 
(Fig. 7a). When we limited our analysis to gliomas only, 
the significant correlation between TGLI1 and VEGF-C 
was still observed (Fig. 7b) indicating TEM7 levels are 
associated with TGLI1 in tumors. Accordingly, we also 
observed significantly higher levels of TEM7 in GBM 
tumors compared to normal brain (Fig. 7c). As shown 
in Fig. 7d, a representative GBM expressed high levels 
of TGLI1 and TEM7 whereas a normal brain tissue 
lacked expression of both proteins. GEO analysis further 
revealed the novel finding that high TEM7 expression 
predicted poor survival of 161 patients with malignant 
gliomas ( p = 0.03; Fig. 7e). Results in Fig. 7 indicate 
Figure 6: High TGLI1 levels are associated with increased VEGF-C expression in patient gliomas. a. TGLI1 expression 
positively correlates with VEGF-C expression. The tumor microarray used in Fig. 5 was additionally stained for VEGF-C. Pearson 
Correlation was used to correlate TGLI1 with VEGF-C. b. TGLI1 positively correlated with VEGF-C in 122 glioma tissues across all 
grades. Pearson Correlation was used. c. VEGF-C was expressed at higher levels in GBMs compared to normal brain tissues. Student t-test 
was used. d. Representative images of IHC-analyzed tissues. e. GEO data mining of 161 malignant gliomas showed that high VEGF-C 
expression predicted poor patient survival. The log-rank survival analysis was used. Red: tumors with high VEGF-C. Green: tumors with 
low VEGF-C.
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TGLI1 expression is positively linked to TEM7 
expression in patient GBMs and also suggest that TGLI1 
potentially contributes to poor clinical outcome of GBM 
patients through enhancing TEM7 expression, similarly 
to VEGF-C.
DISCUSSION
GBM is primarily characterized by infiltration, high 
rates of proliferation, and abnormal neo-vascularization. 
Efforts have been invested into understanding molecular 
underpinning of these hallmarks of GBM. However, 
the biological understanding of GBM tumors is still 
insufficient, which contributes to the lack of effective 
treatments for the disease. In this study, we report the 
following novel findings: (1) TGLI1, an alternatively 
spliced variant of GLI1 discovered in our laboratory, is 
highly expressed in GBM specimens but undetectable in 
normal brain; (2) TGLI1 promotes GBM angiogenesis; 
(3) TGLI1 transcriptionally activates expression of two 
angiogenic factors, VEGF-C and TEM7, leading to tumor 
angiogenesis; (4) the associations of TGLI1 with VEGF-C 
and TEM7 are observed in cell lines, xenografts and 
specimens of GBM; (5) expression of TGLI1, VEGF-C 
and TEM7 is associated with increased vascularity of 
GBM specimens; and (6) GBM patients with higher 
levels of VEGF-C, TEM7 or CD31 (a vascular endothelial 
marker) in their tumors had worse survival than those with 
low levels. With the aforementioned evidence, this study 
sheds new light into the molecular underpinnings of high 
vascularity characteristic of GBM.
VEGF-C has been functionally linked to both 
angiogenesis and lymphangiogenesis [19, 27–29]. 
VEGF-C and its receptors (VEGFR2 and VEGFR3) have 
been detected in GBM [30–32]. However, how VEGF-C 
is upregulated in GBM has remained poorly understood. 
Whether VEGF-C plays any role in GBM vascularity is 
elusive. In addressing these knowledge gaps, the current 
study provides evidence suggesting an important role that 
TGLI1 may play in upregulating VEGF-C expression in 
GBM and a vital role for VEGF-C as an angiogenic factor 
in GBM. Furthermore, whether VEGF-C is an independent 
predictor for GBM patient survival is currently unknown. 
Importantly, our analysis of GEO datasets showed that 
high VEGF-C expression predicted poor survival of 161 
malignant gliomas. This observation is in line with a 
previous report showing that co-expression of VEGF-C 
with MMP-1 in gliomas was associated with decreased 
Figure 7: TGLI1 levels are positively associated with TEM7 levels in a cohort of patient gliomas. a. TGLI1 expression 
positively correlates with VEGF-C expression. The tumor microarray used in Fig. 5 was additionally stained for VEGF-C. Pearson 
Correlation was used to correlate TGLI1 with VEGF-C. b. A positive correlation was found between TGLI1 and TEM7 in 122 glioma 
tissues across all grades. Pearson Correlation was used. c. TEM7 levels were higher in GBM tumors than in normal brain tissues. Student 
t-test was used. d. Representative images of IHC-analyzed tissues. e. GEO data mining of 161 malignant gliomas indicated that tumors with 
high TEM7 expression were associated with worse patient survival than those with low TEM7 expression. The log-rank survival analysis 
was used. Red: tumors with high TEM7. Green: tumors with low TEM7.
Oncotarget22661www.impactjournals.com/oncotarget
survival [33]. Additional analysis of a larger glioma patient 
cohort is warranted to solidify the role of VEGF-C as an 
independent indicator for poor survival of glioma patients.
Our data indicate VEGF-C has higher expression in 
GBM compared to normal brain tissue and VEGF-C is 
associated with reduced GBM patient survival. We have 
previously shown that TGLI1 also directly upregulates 
VEGF-A [12]. VEGF-A-targeted therapy (primarily 
Avastin) has shown relatively disappointing results 
clinically. Our findings that TGLI1 is also expressed in 
GBM, but not normal brain [11, 14], and drives expression 
of both VEGF-A and VEGF-C may indicate VEGF-C is 
a possible mechanism for resistance to VEGF-A-targeted 
therapy. In the future, it would be beneficial to study 
Avastin-resistant tumors to assess the levels of other 
VEGF isoforms, notably VEGF-C and VEGF-D, which 
has also been shown to be expressed in GBM [34].
Since the central nervous system does not have a 
traditional lymphatic system, VEGF-C function in gliomas 
is likely to promote angiogenesis as well as survival 
and growth of cancer cells expressing VEGF receptors. 
Interestingly, glioma stem cells (GSCs) have been shown 
to be located in the perivascular niche [35, 36]. VEGF-C 
has been shown to be a trophic factor for neural progenitor 
cells [18], possibly indicating that VEGF-C may also play 
a role in GSCs. GSCs promote tumorigenesis, promote 
resistance to GBM therapies, and are associated with 
poor patient survival [37–42]. While activation of the 
hedgehog-GLI1 pathway is associated with GSCs [43], it 
is currently unknown whether TGLI1 is expressed in or 
promotes the formation of GSCs. In light of these notions, 
future studies are needed to explore whether TGLI1 plays 
a role in GSCs and whether this occurs through the ability 
of TGLI1 to transcriptionally activate stemness genes.
TEM7 can be detected in the endothelium of 
multiple types of cancer [25, 44–46], some neuronal 
populations of the vertebrate brains [26, 47], and also in 
tumors [23]. TEM7 is a type I transmembrane protein with 
a large extracellular domain, but has been shown to express 
intracellularly and be secreted [22]. Although its biological 
function is still unclear, TEM7 has been shown to interact 
with extracellular matrix components and may play a role 
in cell migration, invasion, and capillary morphogenesis 
[23–26]. TEM7 has been linked to neuronal stem cells [26, 
47]. High expression of TEM7 in osteogenic sarcomas was 
associated with poor survival and high-grade tumors [23]. 
However, the extent of TEM7 expression in GBM is not 
known and the relationship between TEM7 and GBM 
patient survival is presently unknown. In this study, 
we report that TEM7 is expressed in gliomas whose 
expression is upregulated by TGLI1, and that TEM7 is 
potentially an important mediator of GBM angiogenesis 
and also a predictor for poor survival of glioma patients. 
These important observations warrant future investigations 
into the precise biological functions of tumoral TEM7 in 
the context of GBM angiogenesis and potentially other 
malignant phenotypes of GBM. For example, TEM7 may 
potentially play a role in GBM invasiveness and GSCs. 
The invasion front of GBMs is also thought to be another 
niche wherein GSCs are located and expand the tumor by 
invasion of the surrounding tissue [48]. Since TEM7 has 
been shown to play a role in cell invasion [24, 25, 49] 
and neuronal stem cells [26, 47], it is an important task to 
investigate whether TEM7 promotes GBM invasiveness 
and potentially the GSC niche in this compartment.
Since our discovery of TGLI1 in 2009, we have 
uncovered several important properties and functions of 
TGLI1. We showed that TGLI1 is highly expressed in 
cell lines and specimens of GBM and breast cancer, but 
undetectable in normal counterparts [11–14]. We further 
reported that TGLI1 behaves as a gain-of-function GLI1 
transcription factor that regulates not only known GLI1 
target genes but also additional genes not targeted by 
GLI1, including CD24, VEGF-A, VEGFR2, and HPA 
[11–14]. Consequently, TGLI1 has been demonstrated 
to promote tumor cell migration, invasion, proliferation, 
and angiogenesis [11–14]. The mechanism by which 
TGLI1 can regulate genes that regulated by GLI1 is 
still unknown. To address this knowledge gap, we are 
currently undertaking studies to determine whether: 1) 
TGLI1 recognizes DNA motifs that are not bound to 
GLI1, leading to transcriptional upregulation of VEGF-C 
and TEM7; and 2) TGLI1 interacts with transcription 
co-factors that GLI1 does not interact with and thereby 
upregulates VEGF-C and TEM7. The mechanism 
by which TGLI1 mediates GBM angiogenesis has 
remained unclear, we undertook the current study using 
an unbiased approach and found that TGLI1 enhances 
expression of VEGF-C and TEM7, leading to abnormal 
neo-angiogenesis often observed in GBM specimens. It 
is worth noting that the angiogenesis gene profiling study 
identified five genes to be down-regulated with TGLI1 
expression. In line with this interesting observation, 
our earlier DNA microarray results indicated that 
23 genes were down-regulated by TGLI1. In light of 
these interesting observations, a future task is to explore 
the role of TGLI1 as a transcription repressor. Since 
microRNAs (miRNAs) can repress gene expression, it is 
also a plausible future direction to explore whether TGLI1 
represses gene transcription by upregulating expression of 
some miRNAs.
In summary, the findings reported in this study and 
our previous studies together have laid the foundation 
for future efforts to investigate: 1) the role of TGLI1 in 
cancer stem cells, 2) the specific splicing mechanisms 
that synthesize TGLI1 in tumor cells but not in normal 
counterparts, 3) the role of TGLI1 in gene repression 
and miRNA expression, 4) the value of TGLI1 as a 
prognostic indicator in human cancers, 5) the potential to 
pharmacologically target TGLI1, and 6) the involvement 




Reagents and cell culture
All chemicals were purchased from Sigma 
(St. Louis, MO) unless otherwise stated. Expression 
vectors, pCMV-Tag2b, pCMV-Tag2b-GLI1, and pCMV-
Tag2b-TGLI1, were generated in our laboratory [11]. 
U87MG cells were purchased from American Type 
Culture Collection (ATCC) and were maintained 
in DMEM (Gibco) supplemented with 10% FBS 
(Gemini) and 1% penicillin/streptomycin (Gibco). The 
siRNAs for TEM7 (GUGCCAGAAUCUCGGCGAA) 
and VEGF-C (CCAAUUACAUGUGGAAUAA) 
were purchased from Thermo Scientific (Lafayette, CO). 
The non-targeting control siRNA was obtained 
from Bioneer (Alameda, CA) with the sequence of 
CCUACGCCACCAAUUUCGU(dTdT).
Angiogenesis PCR array
Total RNA was isolated from the xenograft tumors 
(three per group) using the SV Total RNA Isolation 
System (Promega). Complementary DNA (cDNA) 
was produced from 1 μg total RNA using the RT2 first 
strand kit (SABioscience). The cDNA was then analyzed 
on a human angiogenesis RT2 Profiler PCR Array 
(SABioscience) using a Stratagene Mx3005p qPCR 
system (Stratagene). The PCR array detected 84 genes 
related to angiogenesis and is specific to human genes 
without cross-reactivity with genes of other species. 
The genes found to be significantly different (> 2-fold; 
p < 0.05) between U87MG-TGLI1 and U87MG-GLI1 
xenografts were further analyzed using RT-PCR.
GEO analysis of gene expression profiles and 
patient overall survival
We compiled a DNA microarray dataset of 
185 patient malignant gliomas, with 135 being GBM, from 
GEO (GSE4271 [16] and GSE4412 [17]). The datasets 
were normalized using MAS5.0 and each microarray was 
centered to the median for all probes, as we previously 
conducted [50]. We performed Pearson Correlation to 
determine the relationships between selected genes using 
Microsoft Excel. Of the 185 total patients included in this 
compiled cohort, 161 patients had survival data accessible. 
Using data from these 161 patients (114 GBMs and 47 
grade III gliomas), we performed the log-rank survival 
analysis for CD31, VEGF-C, and PLXDC1 (TEM7) 
genes using Prism GraphPad version 5. A histogram for 
the expression of each gene was used to determine a 
rational cut point for high or low expression of each gene 
for survival analysis. The cutoffs used for CD31, VEGF-C 
and TEM7 were 50%, 86% and 75% respectively.
RT-PCR
Total RNA isolation was conducted using SV Total 
RNA Isolation system (Promega) and RT was done with 
Superscript III First-Strand cDNA synthesis system 
(Invitrogen). The following primers were used for PCR: 
TEM7: Forward 5′-GGAGTGGATGGACTATGGCT-3′ 
Reverse 5′-AGGGAGGAGGAGGTAGTGGT-3′ VEGF-C: 
Forward 5′-GGCTGGCAACATAACAGAGA-3′ 
Reverse 5′-GTGGCATGCATTGAGTCTTT-3′ β-actin: 
Forward 5′-GGCGGCACCACCATGTACCC-3′ Reverse 
5′-AGGGGCCGGACTCGTCATACT-3′.
Immunoblotting
Immunoblotting was done as we described 
previously. [14] Antibodies used include VEGF-C (R&D), 
TEM7 (Novus Biologicals), HPA1 (Santa Cruz; H-80) and 
β-actin (Sigma).
Immunohistochemistry and tissue microarray
Tumor sections were deparaffinized and 
immunohistochemistry (IHC) was conducted as we 
described previously [14]. Tissue microarrays (US 
Biomax; GL2083) were deparaffinized followed by 
probing with antibodies for goat polyclonal VEGF-C 
antibody (R&D; AF752; 1:50), mouse monoclonal TEM7 
antibody (Novus Biologicals; NB 100–56557; 1:75), 
rabbit polyclonal CD31 antibody (Thermo Scientific, 
Clone JC/70A, ready-to-use), and rabbit polyclonal HPA1 
antibody (Santa Cruz; H-80; 1:25). TGLI1 antibodies 
were developed by us as we previously described [14]. 
Histologic scores (H-scores) were computed from percent 
positivity (A%, A = 1–100) and intensity (B = 0–3) using 
the equation, H-Score = A x B. MVD was calculated by 
determining the area (mm2) of each tissue core on the 
tissue microarray following by manual counting of vessels 
within the entire tissue core. MVD was then calculated as 
the vessels/mm2.
ELISA
Cells were seeded in 24-well plates and incubated 
in EBM-2 basal medium at 37°C for 24 hrs. Conditioned 
medium was then collected and centrifuged at 1200 g for 
10 min. The supernatants were then subjected to Enzyme-
linked immunosorbent assay (ELISA) using a VEGF-C 
ELISA kit (R&D) performed according to manufacturer’s 
instructions. Absorbance was measured using the Synergy 
HT Multi-mode microplate reader (BioTek) at 540 nm 
with 450 nm measurements serving as the background 
normalization. Concentrations were computed with 
reference to a standard curve per manufacturer’s 
instructions for the ELISA kit.
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Chromatin Immunoprecipitation (ChIP)
This was performed using a ChIP Assay kit 
(Upstate, Billerica, MA) as we described previously [14]. 
A GLI1 antibody (Santa Cruz, H-300) that recognizes 
the COOH-terminal region present in both GLI1 and 
TGLI1 proteins was used for immunoprecipitation 
of cells expressing TGLI1, GLI1, or vector. The 
following primers were used to detect presence of 
the VEGF-C gene proximal promoter (within -600 
bp): 5′-GGAGGACAAGAACTCGGGA-3′ and 
5′-TGCCTGCGCTTATGTGAGAGA-3′. The following 
primers were used to amplify TEM7 gene proximal 
promoter (within -600 bp): 5′-GTGGAGGGATAAGGTG 
GAGT-3′ and 5′-GAGAACCCCTAGAAGCATCA-3′.
Tubule formation assay
This was performed using the In Vitro Angiogenesis 
kit (Trevigen), as we previously described [14]. Briefly, 
5000 human brain microvascular endothelial cells were 
seeded into each coated well. Conditioned medium was 
collected after incubation with tumor cells for 24 hours 
and then added to the endothelial cells for 4–6 hrs. 
Endothelial cells were then photographed under a light 
microscope. Images were analyzed for tubule formation, 
which was quantified by measuring total tubule length 
and total number of branch points using ImageJ software. 
Experiments were completed in triplicate.
Statistical analysis
Data are presented as mean ± SE. The student t-test 
and Pearson Correlation were performed as necessary 
using STATISTICA (StatSoft) and Microsoft Excel. For 
survival correlations, the log-rank survival analysis was 
performed using Prism GraphPad version 5. Significance 
was set at p < 0.05.
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